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J. Moss a,*, P. Kalra b, S. Chakraverty cAt ﬁrst sight the question appears naïve and certainly there
is consensus that a kidney with no blood supply is not going
to function. But what if the blood ﬂow is just reduced, that
is, by a renal artery stenosis (RAS), what does that mean for
a patient and should it be corrected by arterial stenting?
The much awaited CORAL (Cardiovascular Outcomes in
Renal Atherosclerotic Lesions) trial published recently in the
New England Journal of Medicine1 concluded that in pa-
tients with a >60% atherosclerotic RAS and either hyper-
tension and/or impaired renal function gained no additional
beneﬁt from renal artery stenting over medical therapy
alone. This is not an unfamiliar story and adds one more
trial to the list of ﬁve that have been unable to demonstrate
any beneﬁt from renal stenting for atherosclerotic RAS.2e6
CORAL is the largest trial to date (n ¼ 947), and used a
composite end point of mortality and major non-fatal car-
diovascular and renal events as its primary outcome mea-
sure. ASTRAL (Angioplasty and Stent for Renal Artery
Lesions; n ¼ 806) and STAR (Stent Placement in Patients
With Atherosclerotic Renal Artery Stenosis and Impaired
Renal Function; n ¼ 140) used renal function as the primary
outcome, but, irrespective of the outcome measure, all
these trials have come to the same conclusion of no
beneﬁt. Although the procedural clinical adverse event rate
in CORAL was very low, both ASTRAL and STAR reported
several serious clinical adverse events in stented patients,
including occasional deaths.2,3 However, the procedural
complication rate (vessel dissection, occlusion, distal
embolization, etc.) was 5.2% in CORAL, a ﬁgure similar to
that seen in ASTRAL.
No one likes a negative study, and even more so when
the results sound counterintuitive, surely it must be good
medicine to correct an impaired blood supply to an organ?7
What are the possible ﬂaws with these six trials? Initial
criticism of the earliest trials (EMMA [Essai Multicentrique
Medicaments vs Angioplastie], Scottish and Newcastle
study) was leveled at the unlikelihood that plain old balloon
angioplasty would lead to a sustained correction of the
anatomical lesion and we had to await the advent of stents
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trials (DRASTIC [Dutch Renal Artery Stenosis Intervention
Cooperative], STAR, ASTRAL, and CORAL) failed to demon-
strate beneﬁt? Perhaps the wrong patients were put into
these trialsdpatients who had relatively minor degrees of
RAS who might not be expected to beneﬁt? The ASTRAL
trial did not specify a lower limit for the degree of stenosis,
but nearly 60% of the patients had a stenosis of >70%, and
the lower limit in CORAL was 60%. ASTRAL found no dif-
ference in outcome with respect to baseline pre-speciﬁed
subgroup stenosis severity and also in a post hoc sub-
group analysis of 163 patients with more “severe” anatomic
lesionsdbilateral >70% stenosis or unilateral >70% RAS in
a single kidney. CORAL looked at a pre-speciﬁed group of
“global renal ischemia” deﬁned as >60% stenosis either
affecting both kidneys or a single functioning kidney, and
again failed to demonstrate any beneﬁt in this subgroup. So
criticisms of the wrong patients entering these trials seem
hard to supportdat least in terms of severity of anatomical
RAS. Do we know if patients who were stented outside of
these trials beneﬁted? A group in Dundee, UK, looked at the
127 patients who were stented outside of ASTRAL (to which
they randomized 35 patients) in the period paralleling the
trial and found no signiﬁcant beneﬁt in this cohort.8 Put
another way, when doctors tried to identify patients whom
they thought would deﬁnitely beneﬁt from stenting they
failed miserably.
There is a big focus on stenosis severity in other vascular
territories, for example carotid and coronary, but perhaps
the kidney is different. When looking at stenosis severity
and renal function Cheung et al.9 failed to show any clear
relationship until the artery had occluded. So the relation-
ship between main vessel narrowing and dysfunction in the
kidney is almost certainly different to that in other organs,
and the term “atherosclerotic renovascular disease” (ARVD)
is, in our opinion, preferable to “atherosclerotic renal artery
stenosis”, allowing other pathological entities, such as
cholesterol embolization and hypertensive small vessel
disease, to be encompassed. Stenting is only going to cor-
rect the stenosis and will not improve small vessel disease
within the kidney, and it may, in fact, aggravate cholesterol
embolization and hypertensive damage.
Another explanation for the lack of beneﬁt in CORAL and
ASTRAL is the effectiveness of vasculoprotective medical
treatment, which appears to have improved outcomes over
time. Back in 2001e02 the annual mortality of patients with
ARVD in the US Medicare population was 16%,10 whereas
annual mortality was 8% in ASTRAL and now only 4% in
CORAL, although the latter trial included patients with
much better preserved renal function than those in ASTRAL
460 J. Moss et al.(estimated glomerular ﬁltration rate 58 mL/minute vs.
40 mL/minute in ASTRAL).
Do any patients beneﬁt from renal artery stenting? The
answer to this is a deﬁnite “yes”, but as there is major
heterogeneity in the clinical make-up of patients with ARVD
it is likely that clinical phenotype is far more inﬂuential in
determining response to renal stenting than is the rather
simplistic degree of anatomical RAS. This is exempliﬁed in a
recent retrospective study of 467 patients with “higher risk”
clinical presentations of ARVD, which showed that acute
pulmonary edema and the combination of rapidly declining
renal function with refractory hypertension (as opposed to
each alone) may be two groups worthy of further study.11
It remains to be seen whether there is any enthusiasm for
another randomized trial of renal stenting, and certainly for
the vast majority of patients tablets and lifestyle modiﬁca-
tion should be the mainstay of care. Nevertheless, further
efforts are required to identify the phenotype of that mi-
nority subgroup of patients who do beneﬁt from renal
revascularization.
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